Novo Nordisk's quarterly report, published on Tuesday evening after the Copenhagen stock exchange closed, shows that the company's sales and operating profit increased by 10 and 6 percent, respectively, in 2025, according to a press release.
The outlook for 2026, however, looks bleaker, with negative growth of 5 to 13 percent for both sales and operating profit, partly due to increased competition and the patent for the weight-loss drug semaglutide expiring in certain markets.
The stock is plummeting on the New York Stock Exchange, where it is also traded. By 6:30 p.m. Swedish time, the stock had fallen more than 14 percent.
